{"_links":{"self":[{"href":"/project/GID-TA11102"}]},"_embedded":{"nice.indev:provisional-schedule-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:provisional-schedule":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Draft guidance","Column2":"16 February 2023 - 09 March 2023","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"Committee meeting: 2","Column2":"04 April 2023","AdditionalInfoLabel":"Meeting number","AdditionalInfo":"2","Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"Expected publication","Column2":"21 June 2023","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:timeline-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:timeline":[{"_links":{"self":[{}]},"ETag":null,"Column1":"24 January 2023","Column2":"Committee meeting","AdditionalInfoLabel":"Meeting number","AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"25 November 2022","Column2":"Joint statement issued by NICE and the SMC/HIS, available in the Project documents.","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"24 August 2022","Column2":"Invitation to participate","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"29 July 2022 - 12 August 2022","Column2":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"29 July 2022","Column2":"In progress. Scoping commenced","AdditionalInfoLabel":"Link text","AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"07 July 2022","Column2":"Awaiting development. Status change linked to Topic Selection Decision being set to Selected","AdditionalInfoLabel":"Link text","AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:process-homepage":{"_links":{"self":[{"href":"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation"},{}]},"ETag":null,"Description":"For further information on our processes and methods, please see our","LinkText":"CHTE processes and methods manual"},"nice.indev:project-team-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:project-team":{"_links":{"self":[{}]},"ETag":null,"Column1":"Project lead","Column2":"Louise Jafferally"}},"ETag":null},"nice.indev:email-enquiry-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:email-enquiry":{"_links":{"self":[{}]},"ETag":null,"Item":"TATeam4@nice.org.uk"}},"ETag":null},"nice.indev:consultee-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:consultee":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Companies sponsors","Column2":"AstraZeneca (tixagevimab-cilgavimab)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Department of Health and Social Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"NHS England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Welsh Government"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Action for Pulmonary Fibrosis "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Anthony Nolan"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Blood Cancer UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Cardiomyopathy UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Cardiothoracic Transplant Patient Group "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Chronic Lymphocytic Leukaemia Support Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Clinically Vulnerable Families"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Crohn’s & Colitis UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Cystic Fibrosis Trust"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Diabetes UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Evusheld for the UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Immunodeficiency UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Kidney Care UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Kidney Research UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Leukaemia Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Long COVID SOS"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Lupus UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Lymphoma Action"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"MS Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Multiple Sclerosis Trust"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Myeloma UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"National Kidney Federation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"National Rheumatoid Arthritis Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Polycystic Kidney Disease Charity"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Scleroderma and Raynaud’s UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Vasculitis UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Association of British Neurologists"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Association of Cancer Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British HIV Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Infection Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Society for Allergy and Clinical Immunology"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Society for Immunology"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Thoracic Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Cancer Research UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Physicians "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"UK Clinical Pharmacy Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"UK CLL Forum"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"UK Kidney Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"UK Renal Pharmacy Group"}]},"ETag":null},"nice.indev:commentator-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:commentator":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated public health groups","Column2":"None"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"All Wales Therapeutics and Toxicology Centre"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"British National Formulary"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Department of Health, Social Services and Public Safety for Northern Ireland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Healthcare Improvement Scotland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Medicines and Healthcare products Regulatory Agency "},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Scottish Medicines Consortium"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Welsh Health Specialised Services Committee"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Institute of Cancer Research"}]},"ETag":null},"nice.indev:panel-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:panel":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/html-content-3"}]},"ETag":null,"Id":"0f926c50-0c72-40cc-b2d1-4cf7455faca2","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"html-content-3","ConsultationDocumentId":0}},"ETag":null,"Title":"Expected publication","Level":1,"PublishedDate":"2023-02-16T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Expected publication","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:consultation":{"_links":{"self":[{"href":"/guidance/GID-TA11102/consultation/html-content-5"}]},"ETag":null,"Reference":"GID-TA11102","Title":"Tixagevimab plus cilgavimab for preventing COVID-19 [ID6136]","ConsultationName":"Draft guidance","StartDate":"2023-02-16T00:00:00","EndDate":"2023-03-09T17:00:00","ConsultationType":"Draft guidance","ResourceTitleId":"html-content-5","ProjectType":"TA","TechnologyType":"Medicine","ProductTypeName":"Technology appraisal guidance","ShowExpressionOfInterestSubmissionQuestion":false,"DevelopedAs":null,"RelevantTo":null,"ConsultationId":2085,"Process":"STA 2022","HasDocumentsWhichAllowConsultationComments":true,"IsCHTE":true,"AllowedRole":"CHTETeam","FirstConvertedDocumentId":null,"FirstChapterSlugOfFirstConvertedDocument":null,"PartiallyUpdatedProjectReference":null,"OrigProjectReference":null,"AreasOfInterestList":["COV"],"Hidden":false},"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/consultation/html-content-5"},{"href":"/guidance/GID-TA11102/documents/html-content-5"}]},"ETag":null,"Id":"13b20381-024f-4f70-add9-e8aaaf61c843","MimeType":"text/html","FileName":"HtmlContent","Length":2321,"Hash":"0051CDB516A28B04B38312367292E4DA060551DD","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"html-content-5","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft guidance","Level":1,"PublishedDate":"2023-02-16T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2085,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":true,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/129"}]},"ETag":null,"Id":"293e7cd7-82da-41bf-bf34-14bada881e7c","MimeType":"application/pdf","FileName":"ID6136 tix-cil Draft guidance to PM for consultation [noACIC].pdf","Length":337061,"Hash":"7188829241EDE54D7849975A86D69F4530E52E8F","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"129","ConsultationDocumentId":0}},"ETag":null,"Title":"Appraisal consultation document  (PDF version)","Level":1,"PublishedDate":"2023-02-16T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2085,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/97"}]},"ETag":null,"Id":"baf456a2-7e6c-4874-b8c0-ec108d871aa8","MimeType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document","FileName":"ID6136 tix-cil draft guidance to PM for consultation (online commenting version) [noACIC].docx","Length":77939,"Hash":"B289584575E415FC573BA722AA02E152BE6EC371","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"97","ConsultationDocumentId":1}},"ETag":null,"Title":"Appraisal consultation document (online commenting)","Level":1,"PublishedDate":"2023-02-16T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2085,"ConsultationDocumentId":1,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":true,"SupportsComments":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/committee-papers"}]},"ETag":null,"Id":"ef80de36-f9a3-402b-8cef-b546dd024504","MimeType":"application/pdf","FileName":"ID6136 tix-cil DG Committee papers [redacted].pdf","Length":14467013,"Hash":"32427A5407AE19798D1094DD8EF3DFED2C9011EF","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"committee-papers","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers","Level":1,"PublishedDate":"2023-02-16T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2085,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/1"}]},"ETag":null,"Id":"03046627-b45e-492f-a531-2f5506a878f3","MimeType":"application/pdf","FileName":"ID6136 tix-cil ACM1 PART 1 slides for public [redacted].pdf","Length":5053017,"Hash":"05A3B2C5D5ABF8889A973B1136765DF8F95D60F5","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"1","ConsultationDocumentId":0}},"ETag":null,"Title":"Public committee slides","Level":1,"PublishedDate":"2023-02-16T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2085,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/committee-papers"}]},"ETag":null,"Id":"ef80de36-f9a3-402b-8cef-b546dd024504","MimeType":"application/pdf","FileName":"ID6136 tix-cil DG Committee papers [redacted].pdf","Length":14467013,"Hash":"32427A5407AE19798D1094DD8EF3DFED2C9011EF","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"committee-papers","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers","Level":1,"PublishedDate":"2023-02-16T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2085,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance","PanelType":"Evidence","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"ETag":null,"HasResources":false}},"ETag":null,"Title":"Committee meetings","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/html-content-2"}]},"ETag":null,"Id":"e6717790-7c99-4f59-b247-1be2ea90bd0f","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"html-content-2","ConsultationDocumentId":0}},"ETag":null,"Title":"Invitation to participate","Level":1,"PublishedDate":"2023-02-16T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/final-scope"}]},"ETag":null,"Id":"e06207f3-ce45-4c44-abd5-b2da204f7821","MimeType":"application/pdf","FileName":"ID6136 tixa-mab Final Scope to PM for ITP [noACIC].pdf","Length":183600,"Hash":"AA38847613B2AC87D42E32D77213AAE216C0CBCA","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"final-scope","ConsultationDocumentId":0}},"ETag":null,"Title":"Final scope","Level":1,"PublishedDate":"2022-08-24T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/final-matrix"}]},"ETag":null,"Id":"f65c4f7f-c7d2-4441-873a-b2ae852cff4b","MimeType":"application/pdf","FileName":"ID6136 tixa-mab Final Stakeholder list to PM for ITP [noACIC].pdf","Length":236791,"Hash":"9A2B05535013C66AC3488C5FBB8CC1E814221EEB","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"final-matrix","ConsultationDocumentId":0}},"ETag":null,"Title":"Final stakeholder list","Level":1,"PublishedDate":"2022-08-24T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/scope-consultation-comments-and-responses"}]},"ETag":null,"Id":"a23632d3-4675-4569-a036-f340a30c7e69","MimeType":"application/pdf","FileName":"ID6136 tixa-mab Scoping consultation comments to PM for ITP [noACIC].pdf","Length":1206130,"Hash":"20B2A489E2153B1A3463B6B852CFC69C696E5FFA","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"scope-consultation-comments-and-responses","ConsultationDocumentId":0}},"ETag":null,"Title":"NICE's response to comments on the draft scope and provisional stakeholder list","Level":1,"PublishedDate":"2022-08-24T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/equality-impact-assessment-scoping"}]},"ETag":null,"Id":"b6d497dc-1f94-4043-b2c6-6c9837ce68d6","MimeType":"application/pdf","FileName":"ID6136 tixa-mab EIA form (Scoping) to PM for ITP [noACIC].pdf","Length":139505,"Hash":"A7CCEAD1E3F88DBCBB944A70BA025A18B680E84C","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"equality-impact-assessment-scoping","ConsultationDocumentId":0}},"ETag":null,"Title":"Equality impact assessment (Scoping)","Level":1,"PublishedDate":"2022-08-24T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/statement"}]},"ETag":null,"Id":"9fb7d8e2-b068-4801-9749-b478f2dfce6b","MimeType":"application/pdf","FileName":"Joint statement NICE_SMC PrEP.pdf","Length":96041,"Hash":"4BB44D58179CB4FF5D139D0BD984F9343E4AC70D","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"statement","ConsultationDocumentId":0}},"ETag":null,"Title":"Statement from NICE and the SMC/HIS","Level":1,"PublishedDate":"2022-11-25T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Invitation to participate","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/html-content"}]},"ETag":null,"Id":"69dae482-08b6-4e4e-8d70-56ecb1dd44b1","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"html-content","ConsultationDocumentId":0}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","Level":1,"PublishedDate":"2022-07-29T17:12:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1862,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/draft-scope-post-referral"}]},"ETag":null,"Id":"6ced628e-4a65-4eb9-9911-f9ec73471053","MimeType":"application/pdf","FileName":"Appendix B - draft scope.pdf","Length":204375,"Hash":"1A5A61FF358E5BF88190101618B301A6EAD04573","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"draft-scope-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft scope post referral","Level":1,"PublishedDate":"2022-07-29T17:12:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1862,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA11102/documents/draft-matrix-post-referral"}]},"ETag":null,"Id":"357785e0-3b26-4f23-9316-16062ba2fd75","MimeType":"application/pdf","FileName":"Appendix C - Stakeholder list (update 2).pdf","Length":213940,"Hash":"9359F1986FE217657414F1FB6C1D4DA26FE2F975","Name":"default","Reference":"GID-TA11102","ResourceTitleId":"draft-matrix-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft matrix post referral","Level":1,"PublishedDate":"2022-08-10T15:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1862,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true}]},"ETag":null}},"ETag":"01000000-0000-0035-0000-00000000029A","Summary":"Suggested remit: To appraise the clinical and cost effectiveness of tixagevimab and cilgavimab within its marketing authorisation for preventing COVID-19.","Description":null,"ReferralDate":null,"SuspendDiscontinuedReason":null,"SuspendDiscontinuedUrl":null,"SuspendDiscontinuedUrlText":null,"LegacyModel":false,"ProductReference":null,"EvidenceAssessmentGroup":"School of Health and Related Research (ScHARR), University of Sheffield","Reference":"GID-TA11102","ProjectType":"TA","TechnologyType":"Medicine","ProductTypeName":"Technology appraisal guidance","Process":"STA 2022","Title":"Tixagevimab plus cilgavimab for preventing COVID-19 [ID6136]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-06-21T00:00:00","LastModifiedDate":"2023-02-16T00:01:33.2560217","FirstGoLiveDate":"2022-07-29T17:12:30.9907704","CreatedDate":"2022-07-29T15:39:01.3968744","DevelopedAs":null,"RelevantTo":null,"IdNumber":"6136","AreasOfInterestList":["COV"],"TopicSelectionDecision":"Selected","TopicSelectionReason":"Anticipate","TopicSelectionDecisionDate":"2022-07-07T00:00:00","TopicSelectionFurtherInfo":null,"IndicatorSubTypes":[]}